BenzingaOctober 15, 2026 at 9:20 AM NY12 Days Ago
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $361 price target.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
